dorzolamide / Generic mfg. - LARVOL DELTA

Targeting Carbonic Anhydrase II–BCL3–β‑Catenin Axis with Dorzolamide to Overcome Temozolomide Resistance in Glioblastoma Cells and CD133+ Stem‑Like Cells (SNO 2026) - No abstract available

Brain Cancer • Glioblastoma • Solid Tumor • BCL3 • CD133 • CTNNB1

Novel Dual-Device Strategy: Failed PRESERFLO MicroShunt Connected to an Ahmed ClearPath - Case Report. (PubMed, Case Rep Ophthalmol) - "Intraocular pressure decreased to 5-9 mm Hg and remained stable under minimal medication (dorzolamide eyedrops 3×/d) at the 3 months postoperative follow-up visit...The described dual-device strategy preserved conjunctival tissue and obviated the need for a second tube in the anterior chamber. This approach represents an effective and tissue-sparing alternative for patients in whom a PRESERFLO® MicroShunt is well positioned but rendered insufficient by scarring."

Journal • Glaucoma • Ophthalmology

Comparative efficacy of different treatment modalities in the management of macular oedema in retinitis pigmentosa: a systematic review and network meta-analysis. (PubMed, BMJ Open Ophthalmol) - "CAIs and DEXi demonstrated the greatest long-term anatomical benefit for RP-associated macular oedema, whereas durable BCVA gains remained limited across available therapies. While oral and topical CAIs showed comparable short-term efficacy, topical dorzolamide and DEXi provided greater long-term CMT reduction than oral CAIs. Given the limited number of studies and small sample sizes, these findings should be interpreted cautiously and validated in larger randomised controlled trials."

Clinical • Journal • Retrospective data • Review • Genetic Disorders • Inherited Retinal Dystrophy • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Challenges and opportunities for developing selective carbonic anhydrase inhibitors and activators for vertebrate isoforms. (PubMed, Enzymes) - "Carbonic anhydrase (CA, EC 4.2.1.1) inhibitors of the sulfonamide/sulfamate type, such as acetazolamide, thiazides/high-ceiling diuretics, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, antiepileptics (sulthiame, topiramate, zonisamide), or non-steroidal anti-inflammatory agents such as celecoxib and polmacoxib, are effective inhibitors of most CA isoforms present in vertebrates but their clinical use in various pathologies is associated with side effects. Significant efforts were done in the last decades for developing isoform-selective inhibitors for all 12 catalytically active mammalian isoforms, with important results being obtained by using the tail approach or by the discovery of new inhibitory chemotypes, such as the coumarins and their derivatives, the boron/selenium-containing compounds, etc. SLC-0111, an antitumor sulfonamide in clinical development is an example of a successful strategy emerged by using the tail approach, this..."

Journal • Review • CNS Disorders • Cognitive Disorders • Mood Disorders • Obsessive-Compulsive Disorder • Oncology • Post-traumatic Stress Disorder • Psychiatry

Carbonic anhydrases I and II. (PubMed, Enzymes) - "Many CA inhibitors are in clinical use for the management of such conditions, among which are acetazolamide, thiazides and high-ceiling diuretics, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, and antiepileptics such as sulthiame, topiramate and zonisamide, whereas SLC-0111 is in clinical development as an antitumor agent. CA activators are not yet used clinically, but they might have pharmacological applications in the management of neurodegeneration, emotional memory disorders, obsessive-compulsive disorders, phobias, generalized anxiety, and post-traumatic stress. Finding novel modulators of activity for these enzymes may lead to innovative therapeutic applications and deepen our understanding of enzymes, their inhibitors, and their activators."

Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Epilepsy • Genetic Disorders • Glaucoma • Hypertension • Immunology • Inflammatory Arthritis • Mood Disorders • Neuralgia • Obesity • Obsessive-Compulsive Disorder • Obstructive Sleep Apnea • Oncology • Ophthalmology • Osteoporosis • Pain • Post-traumatic Stress Disorder • Psychiatry • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Sleep Disorder

Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH (clinicaltrials.gov) - P4 | N=140 | Active, not recruiting | Sponsor: Tecnoquimicas

New P4 trial • Cardiovascular • Glaucoma • Ophthalmology

ICRF-Assisted Box-Behnken Design and Optimization for Rapid UPLC-PDA Determination of Dorzolamide Hydrochloride and Timolol Maleate in an Ophthalmic Preparation. (PubMed, J AOAC Int) - "The study demonstrates the effectiveness of composite response-based chemometric optimization in enhancing analytical efficiency in pharmaceutical drug analysis."

Journal • Ophthalmology

Synergistic antidiabetic efficacy of dorzolamide and metformin: HPTLC quantification and biological evaluation. (PubMed, Sci Rep) - "This investigation is the first to demonstrate the antidiabetic synergy of DOR and MET, supported by biochemical, histological, and chromatographic evidence. The validated HPTLC‑densitometric method provides a simple, sensitive, and cost‑effective tool for routine analysis, while the biological findings highlight a promising therapeutic strategy for DM management."

Journal • Diabetes • Glaucoma • Metabolic Disorders • Ophthalmology

Hypotony following the use of topical carbonic anhydrase inhibitors in glaucoma patients: a case report and review of literature. (PubMed, Int J Surg Case Rep) - "Early recognition and prompt medication withdrawal can prevent permanent structural damage and preserve vision. The accompanying literature review highlights CAIs, particularly dorzolamide, as a rare but significant cause of hypotony."

Journal • Glaucoma • Macular Degeneration • Ophthalmology • Retinal Disorders

Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data. (PubMed, Ophthalmol Ther) - "These findings suggest that treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension may differ depending on the IOP-lowering regimen."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Post-Marketing Surveillance Reveals Amplified Adverse Event Burden Across Topical Pharmacotherapies for Primary Open-Angle Glaucoma (ARVO 2026) - "The FDA-approved drugs evaluated included bimatoprost, tafluprost, travoprost, latanoprost, omidenepag, timolol, brimonidine, brinzolamide, dorzolamide, netarsudil, brinzolamide-brimonidine, and brimonidine-timolol. With average trial lengths of 15 months versus chronic real-world use, post-marketing data reveal multisystem and mortality-associated safety signals not detected pre-approval. These findings highlight gaps in the POAG trial safety reporting and may support the need for extended pharmacovigilance beyond formal trial periods."

Adverse events • P4 data • Glaucoma • Ophthalmology

Impact of Carbonic Anhydrase Inhibitor Therapy on Visual Acuity in Retinitis Pigmentosa Patients with Cystoid Macular Edema (ARVO 2026) - "77 of the 90 patients with CME were treated with CAIs, receiving dorzolamide (n=54), acetazolamide (n=16), methazolamide (n=3), or dorzolamide and acetazolamide (n=4). CAI therapy failed to demonstrate significant benefit to BCVA even in patients with anatomical improvement. Further investigation of the mechanisms of visual decline in RP-associated CME may be needed to optimize treatment strategies."

Clinical • Inherited Retinal Dystrophy • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Sod2 plays a significant role in corneal endothelial cell protection (ARVO 2026) - "Pump function was assessed by stromal lactate retention, and by measuring the increase in CT after addition of Dorzolamide (carbonic anhydrase inhibitor)...These changes are associated with an early alteration in endothelial barrier function and a late compromise of the pump function. Sod2 plays a significant role in corneal endothelial cell protection."

Ophthalmology • SOD2 • TJP1

Outcomes of Fixed Timolol–Dorzolamide–Brimonidine Therapy in a Tertiary Glaucoma Center: A 6-Year Real-World Cohort Study. (ARVO 2026) - "Conclusions In this large real-world cohort, the fixed combination of timolol, dorzolamide, and brimonidine provided substantial IOP reduction, with more than half of eyes reaching an IOP ≤18 mmHg and an acceptable safety profile. These findings support its use as a practical option in the routine management of glaucoma and ocular hypertension in tertiary care settings."

Clinical • Real-world • Real-world evidence • Glaucoma • Ophthalmology

Topical Triple Therapy in Small Idiopathic Macular Holes <300 µm: A Retrospective Matched-Cohort Analysis (ARVO 2026) - "Conclusions Topical therapy with dorzolamide, nepafenac, and prednisolone did not demonstrate a statistically significant advantage in anatomical closure rate compared with the untreated cohort in small idiopathic full-thickness macular holes <300 µm. The favorable closure outcomes reported in earlier retrospective studies were not reproducible in this patient population."

Retrospective data • Ophthalmology • Retinal Disorders

Vitiligolike Leukoderma Associated With Chronic Unilateral Topical Ophthalmic Atropine and Dorzolamide. (PubMed, JAMA Ophthalmol) - No abstract available

Journal • Dermatology • Immunology • Ophthalmology • Vitiligo

Allergic Contact Dermatitis From Dorzolamide Without Cross-Reactivity to Brinzolamide. (PubMed, Contact Dermatitis) - No abstract available

Journal • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy and Safety of Carbonic Anhydrase Inhibitors in the Management of Central Serous Chorioretinopathy. (PubMed, J Vitreoretin Dis) - " Carbonic anhydrase inhibitors reduce subfoveal choroidal thickness and central macular thickness in CSCR but do not improve visual acuity or achieve complete fluid resolution. In addition, carbonic anhydrase inhibitors pose a higher risk of adverse events, indicating the need for cautious use and further research on their long-term efficacy and safety."

Journal • Retinal Disorders

Hyaluronic acid-mediated nanocomplexation enhances ocular retention and therapeutic efficacy of dorzolamide in a biodegradable gelatin insert. (PubMed, Int J Biol Macromol) - "Importantly, GelOI-HA/DZ provided stable intraocular pressure reduction for one week, minimizing the peak-trough fluctuations associated with drop therapy. Collectively, this work introduces a rationally engineered hierarchical nano-in-micro ocular system that converts molecular polyelectrolyte complexation into a predictable, zero-order, once-weekly therapeutic platform advancing the design paradigm of long-acting biodegradable ophthalmic drug delivery."

Journal • Glaucoma • Ophthalmology

Depression and Anxiety After Topical Carbonic Anhydrase Inhibitors. (PubMed, Ophthalmol Sci) - "These findings highlight the importance of monitoring neuropsychiatric adverse effects in glaucoma patients receiving topical CAIs. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • CNS Disorders • Depression • Glaucoma • Mood Disorders • Ophthalmology • Psychiatry

Stressing the limits of capillary blood in anti-doping analysis: perspectives on alkylamine-like stimulants and carbonic anhydrase II inhibitors in result management. (PubMed, Front Sports Act Living) - "Comparative concentration-time profiling in urine and capillary blood was performed using isometheptene, a stimulant subject to minimum reporting limits (MRLs), and the carbonic anhydrase II inhibitors dorzolamide and brinzolamide as model compounds...However, capillary blood concentrations did not allow unequivocal discrimination between permitted ophthalmic use and prohibited administration routes. Overall, these findings demonstrate that capillary blood analysis can enhance interpretative context of anti-doping result management, particularly for substances with complex pharmacokinetics, and provide a scientific basis for the future establishment of blood-based reporting criteria."

Journal • Ophthalmology

Stearylamine-Coated Cationic Phyto-Microemulsions Enhance Resveratrol Ocular Delivery for Glaucoma Therapy: Experimental and Preclinical Insights. (PubMed, AAPS PharmSciTech) - "In vivo, SRTPG produced a maximal IOP reduction of 23.88% at 4 h and prolonged efficacy (AUC₀-₈h = 114.28), comparable to dorzolamide. The enhanced performance is attributed to cationic surface charge-mediated mucoadhesion and lipidic microemulsion-facilitated transcorneal transport. SRTPG offer safe, sustained, and penetration-enhanced ocular delivery, with dual IOP-lowering and antioxidant effects, representing a promising nanocarrier platform for glaucoma management."

Journal • Preclinical • Glaucoma • Ophthalmology

Cell-Type-Specific Causal Inference Unveils Novel Targets for Parkinson's Disease. (PubMed, Mov Disord) - "This study contributed to cell-type-specific genetic mechanisms in PD, linking risk variants to molecular alterations and nominating therapeutic targets."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • ARL17A • KANSL1

Real-World Transition to a Preservative-Free Fixed Combination of Dorzolamide/Timolol: Impact on the Ocular Surface Microenvironment, Safety, Tolerability, and Efficacy. (PubMed, Medicina (Kaunas)) - "Satisfaction regarding comfort (≥80%) and handling (≥50%) was high, with 88.0% preferring PF-DT. Transitioning to PF-DT improved ocular surface health while maintaining IOP control, supporting the benefits of preservative-free formulations in restoring microenvironment homeostasis and enhancing tolerability and patient satisfaction."

Journal • Real-world evidence • Dry Eye Disease • Glaucoma • Ophthalmology

Retained cone-responses in homozygous start codon variant in KIZ-associated retinitis pigmentosa. (PubMed, Doc Ophthalmol) - "This case expands the clinical spectrum of KIZ-associated RP by describing the phenotype associated with a homozygous start codon variant. Despite the disruptive nature of the mutation, the patient exhibited a relatively mild rod-cone dystrophy with retained cone responses into the seventh decade. These findings support the inclusion of KIZ in diagnostic panels for autosomal recessive RP and contribute valuable genotype-phenotype correlation data for this rare ciliopathy."

Journal • Genetic Disorders • Inherited Retinal Dystrophy • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa • CTNNA1